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Distinctive profile of the 17-hydroxylase 
and 17,20-lyase activities revealed 
by urinary steroid metabolomes of 
patients with CYP17 deficiency 
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17,20-liase reveladas por meio do metaboloma de esteroides 
urinários de pacientes com deficiência de CYP17
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ABSTRACT
Objectives: (1) Characterize serum (S) and urinary (U) steroid metabolites in complete CYP17 defi-
ciency (cCYP17D); (2) analyze the relative 17α-hydroxylase (17OH) and 17,20-lyase (17,20L) activities 
in vivo; and (3) comparedata from the two most prevalent mutations in Brazil. Subjects and me-
thods: 20 genotyped cCYP17D patients from a previously reported cohort were homozygous for 
W406R or R362C; 11 controls were CYP17 wild types (WT). WT and cCYP17D patients had S and 
U samples drawn to measure: cortisol (F), corticosterone (B), deoxycorticosterone (DOC), 18OH-B, 
18OH-DOC, and 17OHP; and tetrahydro (TH)-B, THA, THDOC, THF+5α-THF, TH-cortisone, androstero-
ne, etiocholanolone, 5-pregnenediol, 17OH-pregnenolone and pregnanetriol. Results: Compared to 
WT, cCYP17D patients had marked elevations of B, DOC, 18OH-B and 18OH-DOC, whereas 17OHP, F 
and adrenal androgens (AA) were reduced; U steroids parallel S findings. Metabolite ratios revealed 
that both 17OH and 17,20L activities were impaired in cCYP17D. There were nodifferences between 
W406R andR362C mutations. Conclusions: cCYP17D patients show parallel overproduction/overex-
cretion of 17-deoxysteroids, and marked reduction of F and AA. In addition to 17OH, 17,20-L activity 
was also impaired in cCYP17D. W406 and R362C mutations disclose similar Sand U patterns. Arq Bras 
Endocrinol Metab. 2010;54(9):826-32
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RESUMO
Objetivos: (1) Caracterizar os esteroides séricos (S) e urinários (U) na deficiência completa da CYP17 
(DcCYP17); (2) analisar as atividades da 17α-hidroxilase (17OH) e 17,20-liase (17, 20 L) in vivo; e (3) 
comparar as duas mutações mais prevalentes no Brasil. Sujeitos e métodos: 20 pacientes genotipa-
dos para a DcCYP17, de uma coorte anterior, eram homozigotos para W406R ou R362C (8 cada); 11 
controles eram CYP17 wild types (WT). Amostras de S e U foram colhidas dos WT e pacientes para 
dosagem de: cortisol (F), corticosterona (B), deoxicorticosterona (DOC), 18-OH-B, 18OH-DOC e 17OHP; 
e tetraidro(TH)-B, THA, TH-DOC, THF+5α-THF, THE, androsterona, etiocolanolona, 5-pregnenediol, 
17OH-pregnenolona e pregnanetriol. Resultados: Comparados aos WT, os pacientes com DcCYP17 
revelaram elevações acentuadas de B, DOC, 18OHB e 18OHDOC, enquanto 17OHP, F e andrógenos 
adrenais (AA) estavam reduzidos. Os esteroides na U acompanham os achados no S. As relações de 
metabólitos mostraram que as atividades de 17OH e 17,20L estavam reduzidas em pacientes com 
DcCYP17. Não houve diferenças entre pacientes com as mutações W406R e R362C. Conclusões: Na 
DcCYP17, a produção e a excreção dos 17-deoxiesteroides estão aumentadas em paralelo, em con-
traste com a reduzida produção/excreção de F e AA. As atividades da 17OH e 17,20-L estão diminuídas 
na DcCYP17. As mutações W406 e R362C apresentam achados semelhantes em S e U. Arq Bras Endocrinol 
Metab. 2010;54(9):826-32
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INTRODUCTION
17-Hydroxylase deficiency (17OHD) is generally considered a rare cause of congenital adrenal hy-
perplasia (CAH). However, it is not so uncommon in 
specific ethnic groups or geographical areas, as among 
the Mennonite descendants of Dutch Frieslanders (1) 
and in Brazil, where 17OHD is considered the second 
most frequent form of CAH, accounting for 5%-7% of 
all cases (2,3).
The disease is caused by mutations in the CYP17A1 
gene which encodes cytochrome P450c17, an enzy-
me expressed in the adrenal cortex and the gonads 
displaying both 17α-hydroxylase and 17,20-lyase ac-
tivities, among others (4-12). The former activity is 
carried out by converting pregnenolone and proges-
terone to 17α-hydroxypregnenolone (17OHPreg) 
and 17α-hydroxyprogesterone (17OHP), respective-
ly, whereas the latter performs the C17-20 side-chain 
cleavage of 17OHPreg to yield DHEA, an androgen 
precursor in the adrenal zona reticulata, ovaries and 
testes. For maximal activities, the enzyme requires a 
functional steroid-binding site domain and a func-
tional redox partner-binding site domain for interac-
tion with the electron-transfer protein P450 oxido-
-reductase and the co-factor cytochrome b5 (7,13-15). 
Most of the 75 reported mutations in CYP17 (16) 
occurs in the steroid-binding domain resulting in 
combined or complete 17α-hydroxylase/17,20-lyase 
deficiency. Thus, failure to produce sex steroids in 
these patients results in sexual infantilism and primary 
amenorrhea in the female (46,XX) and pseudoherma-
phroditism in the male (46,XY) (17-20). In addition, 
impaired production of cortisol − typical of complete 
17OHD −, leads to increased ACTH secretion that 
stimulates overproduction of deoxycorticosterone 
(DOC) and corticosterone (B) − non-17-hydroxylated 
steroid intermediates with mineralocorticoid activity −, 
causing severe hypertension and hypokalemia (2,21-
25). Although the serum steroid profile has been exten-
sively studied in 17OHD, systematic evaluation of the 
full urinary steroid metabolite (metabolome) in these 
patients is limited.
In this paper we determined serum levels and the 
steroid metabolome in a large group of 17OHD pa-
tients and examined specific precursor-to-product me-
tabolite ratios in order to: (1) define possible differen-
ces concerning both enzymatic activities, (2) compare 
metabolite ratios in patients with complete 17OHD 
with those from previously reported patients with iso-
lated 17,20-lyase deficiency (26), and also (3) compare 
the metabolic pattern between the two most prevalent 
CYP17 mutations documented in Brazil, the W406R 
and the R362C.
SUBJECTS AND METHODS
Twenty patients affected with the complete 17OHD 
form of CAH (twelve 46,XY, and eight 46,XX, all phe-
notypic female) were selected from a larger cohort of 
patients previously reported (2). At the time of the stu-
dy, patients ranged in age from 14 to 42 years (median 
of 22 yr); in most, clinical diagnosis had been suspected 
by the absence of secondary sex characteristics and of 
menstrual periods at the time of puberty, mostly asso-
ciated with the presence of hypertension and hypoka-
lemia. Complete 17OHD was established by typical 
laboratory values, as reduced cortisol, aldosterone, and 
plasma renin activity and elevated LH, FSH, and pro-
gesterone, with low to absent sex steroids. All had been 
genotyped and specific CYP17 mutations identified 
(R362C, W406R, R362C+W406R, Y329D+splice, 
Y329X and W406R+M1T) (2).
Eleven normal subjects were also studied as controls 
(5 male; 6 female, 15 to 57 years of age; median of 26 
yr). They were selected among the families of patients 
with 17OHD, but whose genotyping did not identify 
mutations in any of the alleles (“wild types”).
The study protocol was performed in all subjects 
and included urinary collections (mostly spot urine 
samples) to measure steroid metabolites and a mor-
ning blood sampling for serum steroids. All patients 
on ongoing glucocorticoid replacement therapy had 
their medications discontinued for 72h, in an attempt 
to reestablish their pre-treatment steroid profile. Five of 
them had never been treated before.
The study protocol was previously approved by the 
Committee on Human Research of our institution and 
informed written consent obtained from all partici-
pants.
Analytical methods
All patients and controls had a morning blood sample 
drawn and were instructed to collect a urinary sample 
(a few collected 24-hour urine specimens) and keep it 
under refrigeration until taken to the laboratory. The 
following serum steroids were measured in the Clinical 
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Research Center at San Francisco General Hospital by 
radioimmunoassay after HPLC separation: corticoste-
rone (B), deoxycorticosterone (DOC), 18-hydroxyB 
(18OHB), 18OHDOC, cortisol, aldosterone, and 
17OH-progesterone. 
From each urinary specimen, a 20 mL aliquot was 
passed through a C-18 cartridge for steroid metaboli-
te extraction. Cartridges were subsequently mailed to 
the Children’s Hospital of Oakland Research Institute 
(CHLS) for gas chromatography-mass spectrometry 
analysis. The compounds of interest were identified and 
quantified (concentrations expressed as µg/L of urine) 
and specific steroid ratios were calculated to express 
specific enzymatic activities (27).
The following urinary metabolites were measu-
red: D5-pregnenediol (5PD) and pregnanediol (PD) 
(metabolites of the non-17-hydroxylated precur-
sors, pregnenolone and progesterone, respectively); 
tetrahydro-DOC (THDOC) (metabolite of DOC); 
tetrahydrocorticosterone (THB) and 5α(allo)-THB 
plus tetrahydro-11-dehydrocorticosterone or com-
pound A (THA) and 5α(allo)-THA (metabolites of B); 
17-hydroxypregnenolone (17HP) and pregnanetriol 
(PT) (metabolites of 17-hydroxyprogesterone); te-
trahydrocortisol (THF) and 5α(allo)-THF plus te-
trahydrocortisone (THE) (metabolites of cortisol), as 
well as the urinary metabolites of sex steroids: andros-
terone (AN) plus etiocholanolone (ET) (metabolites 
of androstenedione). 
Enzymatic activities were inferred from calculation of 
the specific precursor-to-product metabolite ratios (Fi-
gure 1). For simplicity, the following groups of metaboli-
tes: (THB+5αTHB), (THA+5αTHA), (THF+5αTHF), 
and THE, will be named herein as “Bs”, “As”, “Fs”, 
and “E”, respectively: (1) (5PD+PD)/(AN+ET) and 
(Bs+As)/(AN+ET) are used as expressions of global 
CYP17 activity (17-hydroxylase plus 17,20-lyase); (2) 
(5PD+PD)/(17HP+PT), PD/PT, and (Bs+As)/(Fs+E) 
stand for the efficiency of 17-hydroxylation solely; and, 
(3) (17HP+PT)/(AN+ET), PT/(AN+ET), and (Fs+E)/
(AN+ET) indicate specifically 17,20-lyase activity. 
The underlined ratios shown above were employed 
to compare data from our patients with those from a 
previous publication that studied patients with “isola-
ted 17,20-lyase deficiency” (26).
RESULTS
Patients with 17OHD showed marked elevations (20- 
to > 100-fold) of serum B, DOC, 18OHB, 18OHDOC 
and progesterone, as compared to WT (Table 1). Con-
versely, cortisol and 17OHP were virtually undetecta-
ble with normal to reduced aldosterone levels. Adrenal 
androgens were also typically low (data not shown).
D5-Pathway:  PREGNENOLONE → 17α-Hydroxylase  → 17α-OH-PREGNENOLONE  → 17,20-Lyase  → DHEA
  (5PD)  (5-PT, not measured)
  ↓ 3b-HSD2  ↓ 3b-HSD2
D4-Pathway:  PROGESTERONE  → 17α-Hydroxylase  → 17α-OH-PROGESTERONE  → 17,20-Lyase  → ANDROSTENEDIONE
 (PD)  (17HP, PT) (AN, ET)
  ↓ 21-Hydroxylase  ↓ 21-Hydroxylase
 DOC  11-DEOXYCORTISOL 
  (THDOC)
 
 ↓ 11b-Hydroxylase  ↓ 11b-Hydroxylase
 CORTICOSTERONE  CORTISOL 
 (THB, 5α-THB= Bs)  (THF, 5α-THF= Fs)
 
  ↓ 11b-HSD2  ↓ 11b-HSD2
 DEHYDROCORTICOSTERONE CORTISONE 
  (THA, 5α-THA= As)  (THE= E)
Figure 1. Schematic illustration of the adrenocortical steroid biosynthesis, identifying steroids produced in the delta-5 and in the delta-4-pathways, the sites 
where 17-hydroxylase and 17,20-lyase operate, the additional hydroxylation steps (in italic), and the respective urinary steroid metabolites (in bold and 
parenthesis). 5PD: 5-pregnenediol; PD: pregnanediol; THDOC: tetrahydro-11-deoxycorticosterone; THB: tetrahydrocorticosterone; 5α-THB: allo-
tetrahydrocorticosterone; THA: tetrahydro-11-dehydrocorticosterone; 5α-THA: allo-tetrahydro-11-dehydrocorticosterone; 5-PT: 5-pregnenetriol; 17HP: 
17-hydroxypregnenolone; PT: pregnanetriol; THF: tetrahydrocortisol; 5α-THF: allo-tetrahydrocortisol; THE: tetrahydrocortisone; AN: androsterone; ET: 
etiocholanolone. 
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Table 1. Basal serum steroid levels (mean  ±  SE and median plus 
interquartile interval) in patients with 17OHD and “wild types” (WT) for the 
disease (all given in ng/dL, except for cortisol, in μg/dL)
Steroid 17OHD(n = 20)
WT
(n = 11) p
B 16,299 ± 1,488
14,800 (4,749-32,900)
358 ± 150
129 (55-1,557)
< 0.001
DOC 323 ± 42
325 (120-921)
4.3 ± 1.0
4.4 (0.4-10.9)
< 0.001 
18OHB 312 ± 40
278 (169-635)
23.5 ± 2.4*
22.1 (10.0-39.7)
< 0.001 
18OHDOC 306 ± 36
276 (126-704)
10.9 ± 5.2
3.1 (2.0-49.4)
< 0.001 
Progesterone 905 ± 94
865 (590-1,330) (30-150 / 30-70)**  
Cortisol 0.3 ± 0.0
0.2 (0.2-0.5)
11.6 ± 1.8
10.4 (4.3-25.7)
< 0.001 
17OHP 2.3 ± 0.3
2.5 (1.0-3.0)
90 ± 23
84 (6-215)
< 0.001 
Aldosterone 3.8 ± 0.8
2.6 (0.2-11.0)
4.6 ± 0.8
5.1 (2.0-10.6)
NS 
* Reference values obtained from ref. 5.
** Normal ranges for male and female controls (at the follicular phase) obtained from ref. 28.
In 17OHD patients, the urinary steroid metabolo-
mes were concordant with their serum findings. Excre-
tion of B metabolites: THA, 5αTHA, THB, and spe-
cially 5αTHB were significantly increased, in parallel 
with THDOC (Figure 2). Accordingly, metabolites of 
the 17-hydroxylase substrates, pregnenolone and pro-
gesterone (5PD and PD) were also significantly increa-
sed (Figure 2). In contrast, cortisol metabolites, THF, 
5αTHF, and THE, were decreased, as well as 17HP 
plus PT and AN plus ET (Figure 3).
Ratios
The (5PD+PD)/(AN+ET) and (Bs+As)/(AN+ET) 
ratios were significantly elevated (4,500- to 8,500-
fold) in 17OHD patients as compared to WT, as a 
result of virtually total CYP17 deficiency (combined 
17α-hydroxylase/17,20-lyase activities) (Table 2). 
The values observed for the latter ratio in patients with 
“isolated 17,20-lyase deficiency” were intermediate 
(around 400-fold higher than WT) (26).
When examined in separate, 17α-hydroxylation 
was predominantly affected over 17,20-lyase activi-
ty, as revealed by the disproportionate increase in the 
(5PD+PD)/(17HP+PT) and (Bs+As)/Fs+E) ratios 
(> 400-fold), as compared to (17HP+PT)/(AN+ET) and 
(Fs+E)/(AN+ET) (4- to 10.5-fold) (Table 2). However, 
17-hydroxylase activity was slightly (PD/PT) to mode-
rately (Bs+As)/Fs+E) affected in patients with “isolated 
17,20-lyase deficiency” (1.7-fold and 37-fold higher than 
WT, respectively). When the PT/(AN+ET) ratio is consi-
dered, 17,20-lyase activity was significantly less impaired 
in our patients with 17OHD than in those with “isolated 
17,20-lyase deficiency” (0.84 [0.64-1.23] vs. 2.25 [1.72-
4.30]), whereas it was similar when the (Fs+E)/(AN+ET) 
ratio is analyzed (8.37[3.44-13.38] vs. 6.63[3.88-14.94]).
When homozygote 17OHD patients for the W406R 
and R362C mutations were compared, all individual 
metabolite values and their respective ratios were simi-
lar and not statistically different.
Figure 2. Urinary steroid levels from 20 patients with 17OHD (dark circles) and 11 normal control individuals (light circles). Left-hand panel – steroid 
metabolites of pregnenolone (Pregnen), progesterone (Prog) and deoxycorticosterone (DOC): 5-PD, PD, and THDOC. Right-hand panel – steroid metabolites 
of corticosterone: THB, 5α-THB, THA, 5α-THA.
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Figure 3. Urinary steroid levels from 20 patients with 17OHD (dark circles) and 11 normal control individuals (light circles). Left hand panel - steroid metabolites 
of 17-OH-progesterone (17HP and PT) and androstenedione (AN and ET). Right hand panel – steroid metabolites of cortisol: THF, 5α-THF and THE.
Table 2. Relative enzymatic activities of CYP17 as determined by diagnostic 
ratios of urinary steroid metabolites (median plus interquartile interval) in 
patients with 17OHD, “isolated 17,20-lyase deficiency” (17,20-LD*) and 
“wild types” (WT) for the disease
Urinary steroid
metabolite ratios
17OHD
(n = 20) 
17,20-LD*
(n = 6) 
WT
(n = 11)
CYP17 (17-hydroxylase+17,20-Lyase) 
(5PD+PD)/(AN+ET) 243.6 
(130.3-315.8)
– 0.14 
(0.10-0.22)
(Bs+As)/(AN+ET) 714.5 
(348.3-1,136.8)
58.4 
(29.6-67.4) 
0.15 
(0.11-0.28)
17-hydroxylase activity
(5PD+PD)/(17HP+PT) 219.3 
(139.0-296.8)
– 0.53 
(0.42-0.74)
PD/PT 149.2 
(107.8-226.4) 
0.74 
(0.57-1.15)
0.43 
(0.35-0.64)
(Bs+As)/(Fs+E) 94.7 
(63.7-114.4)
8.07 
(5.04-9.66)
0.22 
(0.14-0.24)
17,20-lyase activity
(17HP+PT)/(AN+ET) 1.04 
(0.77-1.48)
– 0.27 
(0.21-0.29)
PT/(AN+ET) 0.84 
(0.64-1.23)
2.25 
(1.72-4.30)
0.20 
(0.17-0.23)
(Fs+E)/(AN+ET) 8.37 
(3.44-13.38) 
6.63 
(3.88-14.94)
0.80 
(0.62-1.26)
5PD: 5-pregnenediol; PD: pregnanediol; AN: androsterone; ET: etiocholanolone; Bs: THB 
(tetrahydrocorticosterone) + 5α(allo)-THB; As: THA (tetrahydro-11-dehydrocorticosterone) + 
5α(allo)-THA; 17HP: 17-hydroxypregnenolone; PT: pregnanetriol); Fs: THF (tetrahydrocortisol) 
+ 5α(allo)-THF; E: THE (tetrahydrocortisone).
* Ratios derived from data reported in ref. 26. 
DISCUSSION 
In this study we examined the serum steroid levels and 
the urinary steroid metabolomes from 20 patients with 
17OHD, in whom enzymatic activity was proven to be 
completely abolished by the specific CYP17A1 gene mu-
tations W406R and R362C, as reported elsewhere (2). 
The serum steroid profile was comparable to tho-
se previously published (8,20,24,25,28) and disclosed 
marked increases of B, DOC and their 18-hydroxy-
-derivatives – 18OHB and 18OHDOC –, the so-called 
17-deoxysteroids (from the “mineralocorticoid pa-
thway”) of the zona fasciculata. 
Also confirmed in this study is the dissociation be-
tween the raised levels of 18OHB (aldosterone precur-
sor in the zona glomerulosa) in the presence of reduced 
aldosterone, a unique finding explained by the produc-
tion of 18OHB in the zona fasciculata from its abun-
dant precursor corticosterone, stimulated by increased 
ACTH production (22,23). Since elevated DOC and B 
play a major role in the pathogenesis of mineralocorti-
coid hypertension with hypokalemia and chronic renin 
suppression, zona glomerulosa aldosterone is characte-
ristically reduced in 17OHD (together with a negligi-
ble 18OHB contribution from this zone).
Progesterone is an earlier steroid biosynthetic precur-
sor and the major delta-4 substrate for CYP17. It is in-
variably increased in patients with 17OHD regardless of 
gender, and also frequently elevated in other adrenal en-
zymatic deficiencies. The marked progesterone increase 
found in our patients corroborate data reported by Martin 
and cols. (28) who suggested that elevated progesterone 
in the presence of hypergonadotrophic hypogonadism is 
a simple yet strong evidence for the diagnosis of 17OHD. 
In isolated 17,20-lyase deficiency progesterone is also ele-
vated, mostly after ACTH stimulation, but suspicion is 
Steroid metabolites in CYP17 deficiency
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best raised when the 17OHP to androstenedione ratio is 
increased, as suggested by Auchus and Miller (6).
The urinary steroid metabolomes evaluated in 
this study were in agreement with serum findings, im-
plying an appropriate hepatic, renal and peripheral me-
tabolism of the steroid mixture. Urinary metabolites of 
early biosynthetic steroids, such as pregnenolone and 
progesterone (5PD and PD), are substantially increased 
in 17OHD patients. Also, both B metabolite isomers, 
the reduced (THB, 5αTHB) and the dehydrogenated 
(THA, 5αTHA) forms, are distinctly elevated, as well as 
THDOC. The magnitude of metabolite excretion of the-
se steroid is somewhat disproportional and less expressive 
than that seen with serum levels (25-fold vs. 65-fold hi-
gher than WT, respectively), possibly reflecting the broad 
dispersion into several other metabolites and/or an une-
ven excretory processing. Nevertheless, the preferential 
5α-reduction catabolic pathway remains functionally ac-
tive, if not increased, in these patients.
On the other hand, both cortisol and androgen 
metabolites are appreciably reduced in patients with 
complete 17OHD, reflecting their virtually absent pro-
duction. In addition, the 17-hydroxylated intermedia-
te metabolites, especially 17OH-progesterone (17HP 
and PT), are also substantially reduced.
The relative enzymatic activities of CYP17 
(17-hydroxylase and 17,20-lyase) were estimated by 
analyzing specific precursor-to-product metabolite ra-
tios. This in vivo assessment has proven useful for the 
diagnosis of several biosynthetic defects (26,27).
The precursor-to-product metabolite ratios that esti-
mate global enzymatic activity in patients with 17OHD 
showed very high and unequivocal values – in the range 
of 4,000- to 8,000-fold higher than WT –, typical of a 
complete loss of CYP17 function. A separate evaluation 
of 17α-hydroxylase and 17,20-lyase activities in the same 
patients, also demonstrates expressive enzymatic defi-
ciencies (increases of proper metabolite ratios); however, 
they were at least one and two orders of magnitude less 
(400- to 900-fold and 3- to 10-fold, respectively) than 
complete 17OHD, denoting a predominant 17-hydro-
xylase obliteration. The lower yet significant increased 
ratios for the latter is not surprising since the amount of 
substrate for this second reaction (17,20-lyase) would be 
reduced as a result of deficient 17-hydroxylation.
For comparison with the report by Tiosano and 
cols. (26) who studied patients initially assumed to 
have isolated 17,20-lyase deficiency, we examined sli-
ghtly different metabolite ratios which, nevertheless, 
express similar enzymatic functions. Using this set of 
data, global enzymatic activity was much less affected 
in Tiosano’s patients than in ours: although nearly 400-
fold higher than in WT, the Bs+As/AN+ET ratio in our 
patients was 12-fold higher than in theirs. 
Analysis of the 17-hydroxylase activity alone also 
confirms the previous findings observed for 17OHD 
patients as compared to WT (~400-fold higher in the 
former). However, in the six patients reported by Tio-
sano and cols. (26), these ratios reach values 1.7- to 37-
fold higher than WT, indicating a partial 17-hydroxylase 
deficiency, an observation already made by the authors. 
Concerning 17,20-lyase activity, the PT/(AN+ET) 
ratio was the only one that discloses higher values in 
Tiosano’s patients than in ours (11-fold vs 4-fold in 
comparison with WT, respectively), indicating the pre-
dominant impairment of 17,20-lyase over 17-hydro-
xylase, or in other words, a greater availability of 
17-hydroxylated products in Tiosano’s than in our 
17OHD patients. Similar but less evident results could 
be observed with the Fs+E/AN+ET ratio.
In this regard, it is tempting to speculate that some 
patients with “complete 17OHD” may in fact have “iso-
lated 17-hydroxylase deficiency”, in analogy to those with 
“isolated 17,20-lyase deficiency” reported by Tiosano in 
whom the E305G mutation in the CYP17A1 gene was 
shown in vivo to affect also 17-hydroxylation, althou-
gh in vitro studies indicate normal activity (29). Indeed, 
both activities may have an impairment spectrum as a 
result of different CYP17A1 mutations, since the rarity of 
“true” isolated 17,20-lyase deficiency (14,15) precludes 
systematic metabolic studies. Also, in at least one family 
previously diagnosed as having 17,20-lyase deficiency, 
reinvestigation showed a homozygous mutation G539R 
in the gene of P450 oxidoreductase (30).
The urinary metabolome and the metabolite ratios 
studied in this paper confirm previous in vitro findings 
of absent 17-hydroxylase and 17,20-lyase activities in 
17OHD patients. However, as observed by Tiosano 
and cols. (26), data derived from these in vivo studies 
seem more precise than those obtained from enzymatic 
expression in vitro (26). This observation allows the as-
sumption that many enzymatic processes are under the 
influence of multiple modulators or modifying factors 
and characterize the variability of the individual pheno-
type sometimes associated to the same mutations. 
In spite of these observations, data analysis from 
the two more prevalent mutations in Brazilian patients 
with 17OHD, both known to abolish CYP17 enzyma-
tic activity, did not evidence any significant differences 
between groups.
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In conclusion, patients with 17OHD disclose pa-
rallel overproduction and overexcretion of the adreno-
cortical 17-deoxysteroids (“the mineralocorticoid pa-
thway of zona fasciculata”), in contrast with a marked 
decrease in the production and excretion of cortisol 
and adrenal androgens. In addition to 17-hydroxyla-
tion, 17,20-lyase activity is also impaired in complete 
17OHD. Homozygote patients for the CYP17 muta-
tions W406 and R362C, both associated with absent 
17OH activity, disclosed a similarly abnormal pattern 
of serum steroids and urinary metabolites. 
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